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Abstract
Background: Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but
also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels of
preexisting immunity in prostate cancer patients vaccinated with the HER-2 hybrid peptide (AE37), during a phase I
clinical trial. The purpose of the current study was to correlate between preexisting immunity to the native HER-2
peptide, AE36, and expression of HLA-A2 and -A24 molecules with the clinical outcome. Additionally, we investigated
the ability of the AE37 vaccine to induce an antitumor immune response against other tumor associated antigens, not
integrated in the vaccine formulation, with respect to the clinical response.
Methods: We analyzed prostate cancer patients who were vaccinated with the AE37 vaccine [Ii-Key-HER-2/neu(776–790)
hybrid peptide vaccine (AE37), which is a MHC class II long peptide vaccine encompassing MHC class I epitopes,
during a phase I clinical trial. Preexisting immunity to the native HER-2/neu(776–790) (AE36) peptide was assessed by IFNγ
response or dermal reaction at the inoculation site. Antigen specificity against other tumor antigens was defined using
multimer analysis. Progression free survival (PFS) was considered as the patients’ clinical outcome. Two-tailed Wilcoxon
signed rank test at 95 % confidence interval was used for statistical evaluation at different time points and Kaplan–Meier
curves with log-rank (Mantel-Cox) test were used for the evaluation of PFS.
Results: Preexisting immunity to AE36, irrespectively of HLA expression, was correlated with longer PFS. Specific CD8+ T
cell immunity against E75 and PSA146–151 (HLA-A2 restricted), as well as, PSA153–161 (HLA-A24 restricted) was detected at
relatively high frequencies which were further enhanced during vaccinations. Specific immunity against PSA153–161
correlated with longer PFS in HLA-A24+ patients. However, HLA-A2+ patients with high preexisting or vaccine-induced
immunity to E75, showed a trend for shorter PFS.
Conclusions: Our data cast doubt on whether preexisting immunity or epitope spreading specific for HLA-class
I-restricted peptides can actually predict a favorable clinical outcome. They also impose that preexisting immunity
to long vaccine peptides, encompassing both HLA class II and I epitopes should be considered as an important
prerequisite for the improvement of future immunotherapeutic protocols.
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Background
Cancer immunotherapy aims to immune recognition and
elimination of tumor cells and is a novel approach for ef-
fective management of patients with prostate cancer [1].
Immune tolerance and tumor-induced immunosuppres-
sion often limit beneficial immunotherapeutic protocols
[2]. Therefore, active immunization with antigenic peptides
is a proposed intervention that may help to overcome these
obstacles. HER-2/neu (HER-2) is expressed in a high pro-
portion of prostate tumors and overexpressed in
castration-resistant patients [3–5]. HER-2776–790 (referred
to as AE36) has been shown to induce potent immunologic
responses and chemical hybridization to a tetra-peptide
from the invariant chain of MHC class II molecules
(Ii-key/HER- 2776–790 hybrid peptide or AE37) potenti-
ates furthermore its action [6–8]. In our previous pros-
tate cancer phase I vaccination clinical trial, we showed
that AE37 not only induced potent immunologic responses
[9], but also generated specific antitumor responses that
could be detected even 3 years post booster inoculation
[10]. Patients expressing HLA-DRB1*11 and/or HLA-A24
alleles showed an increased vaccine induced immunological
response which was followed by an increased overall sur-
vival (OS) [11]. Additionally, we found that the AE37 vac-
cine has the potential to induce HER-2 specific CD4+ T
helper cells (Th) that belong to the in vivo immunological
memory repertoire and could even be detected 5 years after
the first vaccine inoculation [12]. Retrospective analyses of
our results revealed that preexisting IFNγ immunity to the
vaccine correlated with OS [13].
Clinical responses in cancer immunotherapies have been
reported to be associated with several post vaccination
biomarkers including frequencies of antigen-specific CD8+
cytotoxic T lymphocytes (CTL), delayed type hypersensi-
tivity test (DTH) and autoimmunity [14–17]. However,
pre-vaccination predictive biomarkers have not been de-
veloped sufficiently until now. Preexisting host immunity
to vaccine candidate peptides before vaccination, has been
proposed as a predictive biomarker of this kind, as it could
act as a basis for the selection of suitable peptides for vac-
cination, in order to induce potent anti-tumor response
that could provide cancer patients with clinical benefit
[14]. Sasada et al. reported a new immunotherapeutic ap-
proach named personalized peptide vaccine, in which they
selected antigen (HLA)-matched vaccine peptides based
on the preexisting host immunity before vaccination and
conducted phase I and II clinical trials, with improved
antigen-specific immune responses and promising clinical
outcomes [15].
CD4+ Th cells have been shown to play a pivotal role
in antitumor immunity [18–21]. They help priming of
tumor specific naïve CD8+ T cells, maintenance of CD8+ T
cell memory and prevention of tolerance. They also induce
proliferation and differentiation of CD8+ T cells into
tumor specific effector CTLs capable for infiltration
into tumor microenvironment [22, 23]. Vaccination
with a HER-2 helper peptide could elicit tumor specific
CTLs via cross-presentation [24]. Hence, vaccine in-
duced immune responses might be directed not only
against the targeted epitope but also against a broad
range of tumor associated epitopes through epitope
spreading [9, 25]. The AE37 peptide vaccine has also
been reported to stimulate CD4+ Th cells rendering
them capable of inducing immunologic memory and
persistent stimulation of CTLs. Vaccine-induced T cells,
secreting mainly Th1 cytokines, may activate dendritic
cells (DCs) hosted in tumor microenvironment. Under
these conditions the phenomenon of cross-presentation
could be enhanced resulting in an epitope spreading [26].
In the current study we investigated a possible correl-
ation between preexisting immunity to AE36 combined
with the expression of certain HLA- molecules and pro-
gression free survival (PFS), in prostate cancer patients,
who had been vaccinated with the AE37 hybrid peptide
during our phase I clinical trial [9]. Additionally, we tried
to answer the question of how preexisting immunity to
other known tumor associated CTL antigens might affect
patients’ clinical outcome and if it can be further enhanced
by AE37 vaccination through epitope spreading.
Methods
Patient samples
The present study involves prostate cancer patients en-
rolled in the phase I clinical trial of the AE37 vaccine
(Ii-Key/HER-2/neu(776–790):Ac-LRMKGVGSPYVSRLLGICL-
NH2), EudraCT2006-003299-37 [9, 11, 27]. The current
study was approved by the Institutional Review Board of
Saint Savas Cancer Hospital. Upon inform consent,
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patients received 6 monthly inoculations (primary vaccin-
ation series; PVS) with AE37 plus GM-CSF as immunoad-
juvant, followed by a single booster inoculation 6 months
after completion of PVS. As previously described, 50 ml of
whole blood was obtained by venipuncture at prevaccina-
tion and at different timepoints during and after vaccina-
tions [9]. PBMCs were isolated from blood samples by
Ficoll (Biochrom) gradient separation at RT, washed
twice in PBS and counted at Neubauer chamber. Viability
was always >95 %. Cells were frozen in FCS/10 % DMSO
at ≥1 × 107 cell/vial at −20 °C for 1 h, transferred at −80 °C
overnight and afterwards stored in liquid nitrogen until
use. PBMCs were thawed in pre-warmed RPM1 1640
culture medium (Gibco® by Life Technologies, Europe)
supplemented with 20 % FCS, 0,5 mM L-Glutamine
(Gibco® by Life Technologies, Europe), and 1X antibiotic-
antimycotic (Gibco® by Life Technologies, Europe,
ref:15240–062)] and counted at Neubauer chamber
using trypan blue. The average viability was >70 %.
HLA typing was performed by PCR-SSP (polymerase
chain reaction-sequence specific primers) as described
previously [11]. Patients' clinicopathological characteris-
tics are presented in Table 1. Clinical progression was
evaluated after enrolment of patients in the clinical trial.
Based on the initial clinical status of each patient, clin-
ical progression was defined as castration-resistance,
metastasis (bone metastasis verified by radiographic
evaluation) or death (Table 1).
IFNγ ELISPOT assay
Preexisting immunity for native HER-2/neu peptide
AE36 (aa776–790: GVGSPYVSRLLGICL) was evaluated
in the IFNγ-based ELISPOT assay, a widely applied tech-
nique for detection of functional effector T cells [13, 17,
28, 29], as previously described [9]. Briefly, freshly iso-
lated PBMCs were cultured in X-VIVO 15 medium
(BioWhittaker, Cambrex) supplemented with 2 % AB
human serum (Sigma), with the AE36 peptide (10 μg/mL)
in precoated IFN-γ ELISPOT plates (MABTECH AB), in
quadruplicates at 2.5 × 105 cells per well. The plates were
incubated at 37 °C in a humidified 5 % CO2 incubator for
40 h and developed as described by the manufacturer.
Spots were enumerated using an ELISPOT analyzer
(A.EL.VIS GmbH) and data are presented as specific spots
(experimental spots minus background spots; i.e., PBMC
in medium alone) per 106 PBMCs. Individual values for
IFNγ production were reported in our previous work [9].
Dermal reaction
Local dermal reactions (LR) were determined 48 h after
each vaccination cycle by measurement of induration, as
previously described [9]. Each inoculation consisted of
500 μg of the AE37 vaccine mixed with GM-CSF as
immunoadjuvant. Given the amount of the peptide along
with the presence of the immunoadjuvant, we consid-
ered LR as a more appropriate method to evaluate HER2
preexisting immunity, compared to the standard DTH
reaction (100 μg AE36 without GM-CSF). Beside this, it
has been previously described that local reaction to the
vaccination site can be used to evaluate immune re-
sponses in the context of immunomonitoring [30, 31].
Therefore, in the present study LR data represent mea-
surements of induration presented as the orthogonal
mean (mm) of the two sites of vaccine inoculation.
Assessment of antigen-specific CD8+ T cells
Antigen-specific T cells were detected by fluorescent MHC-
peptide dextramers, which are multimers based on a dex-
tran backbone bearing multiple fluorescent moieties [32].
Such multimers are ideal for analyzing extremely low fre-
quencies of antigen-specific T cells in peripheral blood in
combination with multiparameter flow cytometry [33]. Fre-
quencies of CD8+ cells specific for tumor associated CTL
epitopes, characterized as immunogenic by others and our
group [34–42], were assessed with specific MHC-peptide
dextramers using flow cytometry. The aforementioned as-
sessment of antigen specific T cells was performed on cryo-
preserved samples as part of a retrospective analysis.
Only the most common alleles among our patient cohort,
i.e. HLA-A2+ (n = 12) and HLA-A24+ patients (n = 12, with
two of them co-expressing HLA-A2) were analyzed in this
study, as all other haplotypes were expressed in very few
patients, impossible to give any substantial information.
PBMCs were stained with commercially available MHC
dextramers: A*0201-HER2369–377 (KIFGSLAFL) (referred
to as E75)–FITC, A*0201-PSA146–154 (KLQCVDLHV)-
FITC, A*0201-HER285–94 (LIAHNQVRQV)–PE, A*0201-
HER2435–443 (ILHDGAYSL)-PE, A*0201-PSMA27–35
(VLAGGFFLL)-PE, A*0201-hTERT540–548 (ILAKFLHWL)-
FITC, A*0201-Survivin96–104 (LTLGEFLKL)-PE, A*02402-
PSA153–161 (CYASGWGSI)-FITC, A*02402-Survivin20–28
(STFKNWPFL)-PE (Immudex, Denmark). Briefly, PBMCs
(1–3 × 106) were incubated with 10 μl of MHC dextramer
for 10 min in the dark at room temperature, followed by
staining with specific monoclonal antibodies anti-CD3-
APC (UCHT1), and anti-CD8-PerCP (SK1)(BD Biosci-
ences, Europe) for 20 min in dark at 2–8 °C. Fluorescent
minus one (FMO) samples (without the dextramer) were
used as negative controls. Samples were analyzed by flow
cytometry on a FACSCalibur (BD Biosciences). 50000
CD8+ T cells were collected, thus determining the detec-
tion limit of accurate dextramer+ measurement at ≥0.1 %.
Data analysis was performed using FlowJo software.
Statistical analysis
GraphPad Prism version five software was used for the
statistical analysis of data. Two-tailed Wilcoxon signed
rank test at 95 % confidence interval was used for
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Table 1 Clinical characteristics of patients
Age at
diagnosis












PR02 61 G2T3bN0M0 III 6 (3 + 3) 6 (3 + 3) 12.6 CS A*24 A*32 DRB*07
DRBa15
1+ NP
PR04 64 G2T2bN0M0 II 5 (3 + 2) 5 (3 + 2) —— CS A*02 DRB1*11 DRB1*16 1+ NP
PR05 58 G4T3bN x M1b IV 7 (3 + 4) 7 (3 + 4) 65 CR/M A*24 A*29 DRB1*11
DRB1*14
1+ D (7)
PR06 61 G3T4N1M1b IV 7 (4 + 3) —— 92 CS/M A*02 A*02 DRB1*08
DRB1*11
1+ CR (50)
PR08 51 G2T4N1M0 IV 7 (4 + 3) 7 (4 + 3) 13.30 CS/NM A*24 A*68 DRB1*11
DRB1a14
1+ CR (54)/NM
PR09 73 G4T4N + M0 IV 4 (3 + 1) 9 (5 + 4) 12.3 M A*02 A*26 DRB1*16
DRB1*16
1+ D (18)
PR10 52 G2T3bN1M0 III 6 (3 + 3) 7 (4 + 3) 10.00 CS/NM A*01 A*30 DRB1*04
DRB1*11
1+ CR/M (39)
PR11 73 G3T3bN0M0 III 7 (4 + 3) 7 (4 + 3) 18.85 CS/NM A*02 A*32 DRB1*04
DRB1*07
2+ NP
PR12 55 G2T3bN x M1b IV 7 (4 + 3) —— >200 CR/M A*26 DRB1*11 1+ D (40)
PR13 78 G4T3bN x M1b IV 10 (5 + 5) —— 52.03 CS/M A*02 A*32 DRB1*04 3+ D (9)
PR14 48 G3T3aN0M0 II 6 (3 + 3) 6 (3 + 3) 8.50 CS/NM A*24 A*33 DRB1*03
DRB1*11
1+ NP
PR15 72 G1T1bN0M0 II 3 (2 + 1) —— 18.90 CS/NM A*24 A*29 DRB1*11 2+ NP
PR16 64 T2bN0M0 II 4 (2 + 2) —— 13.40 CS/NM A*24 A*32 DRB1*11
DRB1*15
1+ NP
PR17 49 G4T3bN1M1b IV 9 (4 + 5) —— 12.00 CR/M A*01 DRB1*11 DRB1*13 1+ D (20)
PR18 57 G4T3aN x M1b IV 9 (4 + 5) —— 1000 CR/M A*26 A*32 DRB1*01
DRB1*13
1+ D (21)
PR19 44 G2T3bN1M1b IV 6 (3 + 3) —— 130.00 CR/M A*02 A*24 DRB1*01
DRB1*09
2+ D (13)
PR20 70 G3T2aN0M0 II 8 (4 + 4) 7 (3 + 4) 7.11 CS/NM A*02 A*03 DRB1*04
DRB1*12
2+ NP
PR21 56 G2T2aN0M0 III 8 (4 + 4) 8 (4 + 4) 9.50 CS/NM A*02 A*03 DRB1*15
DRB1*16
1+ NP
PR22 63 G2T3bN0M0 III 6 (3 + 3) 8 (3 + 5) 6.80 CS/NM A*02 A*30 DRB1*15 1+ NP
PR23 63 G3T2bN0M0 II 7 (3 + 4) —— 97.00 CS/NM A*02 A*11 DRB1*04
DRB1*16
3+ LFW (12)
PR24 81 G2T2aN0M0 III 6 (3 + 3) —— 10.00 CS/NM A*01 A*03 DRB1*11
DRB1*16
2+ NP
PR25 75 G3T2aN0M0 II 8 (3 + 5) —— 7.23 CR/NM A*24 A*32 DRB1*04
DRB1*11
3+ NP
PR26 61 G4T3aN x M1b IV 8 (3 + 5) —— 419.83 CS/M A*03 A*11 DRB1*01
DRB1*16
2+ CR/M(45)
PR27 63 G4T2bN0M0 III 7 (4 + 3) 8 (4 + 4) 6.80 CS/NM A*02 A*03 DRB1*11
DRB1*15
3+ NP
PR28 62 G3T3bN0M0 III 8 (3 + 5) 8 (4 + 4) 22.98 CS/NM A*02 A*24 DRB1*16 3+ NP
PR29 67 G2T3bN0M0 III 6 (3 + 3) 10 (5 + 5) 7.50 CS/NM A*03 A*24 DRB1*11
DRB1*13
1+ NP
PR30 66 G2T2bN0M0 III 6 (3 + 3) 6 (3 + 3) 6.00 CS/NM A*24 DRB1*03 DRB1*11 2+ NP
PR31 52 G3T3bN0M0 III 8 (4 + 4) 8 (5 + 3) 6.80 CS/NM A*02 A*24 DRB1*01
DRB1*11
2+ NP
PR32 65 G3T3bN x M1b IV 9 (5 + 4) —— 320.00 CR/M A*24 A*32 DRB1*07
DRB1*10
1+ NP
NP no progression, M metastatic, NM non metastatic, CS castrate sensitive, CR castrate resistant, D death, LFW lost in follow-up
*Clinical status by May 2014. Numbers in parentheses represent months from 1st vaccine to change in clinical status
Voutsas et al. Journal for ImmunoTherapy of Cancer  (2016) 4:75 Page 4 of 15
statistical evaluation of patients at different time points.
Kaplan–Meier curves and log-rank (Mantel-Cox) test
were used for the evaluation of progression-free survival
(PFS). Cut off limits for preexisting (R0) AE36 peptide-
specific T cell frequencies (IFNγ producing cells in re-
sponse to stimulation with AE36 at baseline) and LR at
first vaccine (LR1) were calculated by cut off finder,
http://molpath.charite.de/cutoff/index.jsp. In cases where
the number of samples to be analyzed was <20 and thus
the cut off finder could not be applied, X-tile software was
used for defining the cut off for low- and high frequencies
of tumor antigen-specific (dextramer-positive) CD8+ T cell
populations [43]. Rmax represents the time point during
vaccinations with the highest frequency of antigen specific
T cells detected. The ratio Rmax/R0 was considered high
when value was >2, i.e. when Rmax was at least twofold
above R0 frequency detected. Statistically significant dif-
ferences were considered when the P value was ≤ 0.05.
Results
Preexisting immunity to AE36 affects PFS
Preexisting immunity to AE36 was evaluated by two dif-
ferent approaches. In the first, we evaluated prior to vac-
cination (i.e., time-point R0) ELISPOT-based IFNγ
production, whereas the second was based on the size of
local (dermal) reaction (LR1) 48 h after the first vaccin-
ation. We considered LR1 as a result of preexisting im-
munity to AE36 simply because the time-frame of 48 h
post first vaccination is not sufficient for AE37 (or any
other vaccine) to induce a primary immunologic response
(in this case an AE36-specific response). Using cut off
finder software, the study population was divided into two
subgroups, patients with high or low AE36 preexisting im-
munity, according to the levels of IFNγ production (high
levels: ≥ 25 spots/106 cells) and the size of LR1 (high:
≥10 mm induration diameter). The PFS analysis for a me-
dian follow-up time period of 58 months (range 7–65
months) estimated from the time of first vaccination is
shown in Fig. 1. Median estimated PFS (mPFS) was not
reached in the group of patients having high LR1 (n = 16),
whereas mPFS in the low LR1group (n = 13) was
39 months [p = 0.001, hazard ratio (HR) =0.1222] (Fig. 1a).
mPFS for patients having high IFNγ production (n = 10)
was also not reached, whereas that for low IFNγ pro-
ducers (n = 19) was 50 months (p = 0.0808, HR = 0.3433)
(Fig. 1b). This significant difference for higher mPFS in
the groups of patients with high LR1 or IFNγ preexisting
immunity was much more intense when these patients
were grouped together. Thus, mPFS in the group of pa-
tients having high LR1 and/or IFNγ preexisting immunity
(n = 19) was, as expected, not reached being highly statisti-
cally significant (p < 0.0001) when compared to the group
of patients with low LR1 and low IFNγ preexisting im-
munity (n = 10) (mPFS: 20.5 months; Fig. 1c).
HLA typing was performed on the 29 patients who were
included in our studies. A substantial percentage (23 out
of 29) of those expressed HLA-A2 (n = 13) or HLA-A24
(n = 13), with 3 of them expressing both alleles. For the
patients carrying the HLA-A2 allele, no significant differ-
ence in mPFS was observed compared to non-carriers
(Fig. 2a). However, we found a trend for increased mPFS
among patients expressing the HLA-A24 allele vs those
who were HLA-A24− (Fig. 2b). We next tried to correlate
expression of HLA-A2 and HLA-A24 alleles in
Fig. 1 Preexisting immunity to AE36 affects PFS. Patients having high LR1 showed statistically significant longer mPFS (a). Patients having high
IFNγ production showed a strong trend for longer mPFS (b). Patients having high preexisting immunity (high LR1 or high IFNγ production)
showed statistically significant longer mPFS when compared to the group of patients with low preexisting immunity (c)
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Fig. 2 Correlation between HLA-A2 or A24 expression and preexisting immunity to AE36 with PFS. HLA-A2+ patients had no significant difference
in mPFS compared to HLA-A2− patients (a). However, HLA-A24+ patients showed a trend for increased mPFS compared to HLA-A24− patients (b).
HLA-A2+ patients with high preexisting immunity had statistically significant longer mPFS than HLA-A2+ patients with low preexisting immunity.
HLA-A2− patients with high preexisting immunity showed a strong trend for longer mPFS than HLA-A2− patients with low preexisting immunity
(c). HLA-A24+ patients with high preexisting immunity had a strong trend for longer mPFS compared to HLA-A24+ patients with low preexisting
immunity. HLA-A24− patients with high preexisting immunity showed statistically significant longer mPFS compared to HLA-A24− patients with
low preexisting immunity (d)
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combination with preexisting immunity to the vaccine
and mPFS. HLA-A2+ patients with high preexisting im-
munity had statistically significant longer mPFS than allele
carriers with low (p = 0.0191), whereas a weak trend for
improved PFS was observed between the HLA-A2+ and
HLA-A2− patients with high preexisting immunity. In
addition, in HLA-A2− patients, those with high levels of
preexisting immunity exhibited statistically significant lon-
ger mPFS than those with low ones (Fig. 2c). In an analo-
gous fashion, HLA-A24+ patients with high preexisting
immunity had a strong trend for longer mPFS compared
to those with low levels (Fig. 2d). Interestingly enough,
similar mPFS was observed in patients with high preexist-
ing immunity regardless of HLA-A24 expression (p =
0.7230). Finally, in HLA-A24− patients, those with high
preexisting immunity showed statistically significant better
mPFS than those with low preexisting immunity (Fig. 2d).
To conclude, these data show that preexisting immunity
to the vaccine correlates with longer PFS to all patients
regardless of their HLA allele expression.
Preexisting and AE37-induced immunity to HLA-A2 and
HLA-A24-restricted CTL epitopes
Frequencies of CD8+ T cells specific for known immuno-
genic tumor associated CTL epitopes, not included in the
vaccine, in patients’ peripheral blood were determined by
multiparameter flow cytometry in combination with MHC-
peptide dextramers at each time point (R0, R3, R6, LT). We
used the following MHC-peptide dextramers: A*0201-
HER285–94 (HER285), A*0201-HER2435–443 (HER2435),
A*0201-HER2369–377 (E75), A*0201-PSA146–154 (PSA146),
A*0201-hTERT540–548 (TERT), A*0201-PSMA27–35 (PSMA),
A*0201-Survivin M296–104 (SURV96), A*02402-PSA153–161
(PSA153), A*02402-Survivin20–28 (SURV20).
PBMCs were gated according to their FSC/SSC proper-
ties and then subgated to CD3+ cells which were further
subgated to CD8− (i.e. CD4+) and CD8+ T cells. MHC-
peptide dextramer+ cells were assessed within the gates
representing CD4+ T cells and CD8+ T after substraction
of corresponding negative control values. Initially, we cor-
related MHC-peptide dextramer+ cells at R0 and at any
time-point of maximal response (Rmax) in HLA-A2+ pa-
tients (n = 12). Preexisting frequencies of CD8+ T cells
specifically recognizing the E75 HER-2/neu peptide
(CD8+/E75+ cells) were induced by the vaccine from a
median of 0.59 % (range 0.15–1.49) at R0 to 1.61 %
(range 0.18–2.98) at Rmax (p = 0.0025) (Fig. 3a). Fre-
quencies of CD8+/E75+ cells at each time point (medians
at R3: 0.50 %, R6: 0.83 % and LT: 1.72 %) are shown in
Fig. 3b, with a statistical significant increase at time point
LT vs R0 (p = 0.0177). Representative dot plots for negative
control, R0 and Rmax for patient PR13 are depicted in
Fig. 3c. The AE37 vaccine was also capable of increasing
the frequencies of preexisting CD8+/PSA146
+ cells from a
median of 0.15 % (range 0.04–0.19) at R0 to 0.23 % (range
0.1–0.44) at Rmax (p = 0.0086) (Fig. 3d). CD8+/PSA146
+
cells at each time point (medians at R3: 0.09 %, R6: 0.16 %,
LT: 0.27 %) are shown in Fig. 3e, with a statistically signifi-
cant increase at time point LT vs R0 (p = 0.0547). Repre-
sentative dot plots for negative control, R0 and Rmax
for patient PR6 are depicted in Fig. 3f. In both cases,
percentages of dextramer+ CD4+ T cells, representing
specificity controls, were minimal (Fig. 3b and e).
CD8+/HER285
+ T cell frequencies at R0, were close to the
detection limit of 0.1 % in 8 out of 12 patients (range: 0.02–
0.08 % of CD8+ T cells), whereas in 2 of them, levels were
increased upon vaccination (R0 vs Rmax: 0.08 % vs 0.11 %
and 0.06 % vs 0.14 %) (Additional file 1: Figure S1A). In the
remainder 4 out of 12 patients, CD8+/HER285
+ cells at R0
were at relatively high numbers (0.10–0.19 % of CD8+ T
cells) and in one of them, vaccination increased frequency
levels from 0.17 to 0.40 %. For the total of 12 patients,
CD8+/HER285
+ cells were increased by the vaccine from a
median 0.06 % (range: 0.02–0.19 %) at R0 to 0.12 % (range
0.04–0.4) at Rmax (p = 0.0025) (Additional file 1: Figure
S1A). The levels of specific CD8+ T cells against HER2435,
PSMA, SURV96 and TERT were at marginal levels at all
time-points for the majority of patients, not allowing fur-
ther evaluation (Additional file 1: Figure S1B-E).
Next, we correlated MHC-peptide dextramer+ cells at R0
and Rmax in HLA-A24+ patients (n = 12). CD8+/PSA153
+
cells were induced by the vaccine from a median of 0.44 %
(range 0.0–17.4) at R0 to 1.55 % (range 0.0–15.98) at Rmax
(p = 0.0269) (Fig. 4a). Percentages of CD8+/PSA153
+ T cells
at each time point (medians at R3: 0.53 %, R6: 0.82 %, and
R7: 1.41 %) are shown in Fig. 4b, with statistical significant
increases compared to baseline at time points R6 and LT
(p = 0.0273 and p = 0.0415, respectively). Representative
dot plots for negative control, R0 and Rmax for patient
PR14 are presented in Fig. 4c. Interestingly, prior to
vaccination two patients exhibited high percentages of
CD8+/PSA153
+ cells that either remained unaltered or
slightly increased (Fig. 4d, e). In the majority of pa-
tients, CD8+/SURV20
+ T cells were detected at levels
below 0.1 % prior to vaccination with a median of
0.06 % (range 0.01–0.28) (Additional file 1: Figure S1F).
Concluding, HLA-A2+ patients demonstrated preexisting
immunity for E75 and PSA146 and HLA-A24
+ patients for
PSA153, which was enhanced upon vaccination with AE37
in a statistically significant manner.
How preexisting immunity to HLA-A2 and HLA-A24-
restricted CTL epitopes affects progression free survival
HLA-A2+ patients were grouped according to preexist-
ing immunity to E75 and PSA146. More specifically, pa-
tients exhibiting levels of CD8+/E75+ T cells ≥0.41 %
were considered as having high and those below
0.41 % as low preexisting immunity (x-tile software,
Voutsas et al. Journal for ImmunoTherapy of Cancer  (2016) 4:75 Page 7 of 15
Methods section). With a median follow up of 58 months
for all patients, mPFS of patients with high (n = 8) or low
(n = 4) preexisting immunity to E75 were not reached,
although we observed a trend for shorter PFS among
those who had high preexisting immunity (p = 0.2618,
HR = 4.159) (Fig. 5a). Next, we correlated the ratio
Rmax/R0 for % CD8+/E75+ cells with mPFS. Patients
with high Rmax/R0 ratio (>2; n = 6) had a strong trend
for decreased PFS, compared to patients with low
Rmax/R0 ratio, albeit mPFS was also not reached in
the latter group (p = 0.0833, HR = 7.389) (Fig. 5b).
mPFS of patients having high (≥0.06 %) or low
(<0.06 %) CD8+/PSA146
+ cells (Fig. 5c) and high (>2) or
low (≤2) ratio Rmax/R0 (Fig. 5d) were not reached,
and no statistically significant differences were ob-
served among groups.
Fig. 3 Preexisting and AE37-induced immunity to E75 and PSA146 in HLA-A2
+ patients. Vaccinations induced CD8+/E75+ cells in HLA-A2+ patients
(a). Frequencies of CD8+/E75+ cells at each time point (R0, R3, R6 and LT) (b). Representative dot plots for negative control, R0 and Rmax for patient
PR13 (c). Vaccinations induced CD8+/PSA146
+ cells in HLA-A2+ patients (d). Frequencies of CD8+/PSA146
+ cells at each time point (R0, R3, R6 and LT) (e).
Representative dot plots for negative control, R0 and Rmax for patient PR6 (f)
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Fig. 4 Preexisting and AE37-induced immunity to PSA153 in HLA-A24
+ patients. Vaccinations induced, in a statistically significant manner,
CD8+/PSA153
+ cells (a). Frequencies of CD8+/PSA153
+ cells at each time point (R0, R3, R6 and LT) (b). Representative dot plots for negative control,
R0 and Rmax for patients PR14, PR15, PR16 (c-e)
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Fig. 5 (See legend on next page.)
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HLA-A24+ patients were grouped according to preex-
isting immunity to PSA153. mPFS of patients having high
(>0.04 %, n = 9) preexisting immunity to PSA153 was sig-
nificantly higher (i.e. not reached) compared to patients
with low (≤0.04 %, n = 3) (i.e. 54 months) (p = 0.0017,
HR = 0.0026) (Fig. 5e). Finally, we correlated mPFS with
the Rmax/R0 of CD8+/PSA153
+ cells. There was no differ-
ence in mPFS of patients with high (n = 8) or low ratio
(n = 4) (p = 0.5770, HR = 0.4281) (Fig. 5f ).
Regarding the HLA-A2+ patients, preexisting immunity
to E75 or PSA146, might correlate with shorter PFS. On
the contrary, longer PFS seems to apply for HLA-A24+
patients with preexisting immunity to PSA153.
Discussion
Preexisting immunity along with epitope spreading are
considered important factors securing an effective anti-
tumor response, especially in the context of immuno-
therapeutic peptide vaccination. Beside this, others
propose preexisting host immunity before vaccination as
a basis for the design of efficient vaccination protocols
[14, 15]. In line with this, we have previously shown that
AE37 vaccination offered a clinical benefit in prostate
cancer patients, with high levels of preexisting immunity
to the native AE36 peptide detected by IFNγ ELISPOT
[13]. It is worth mentioning, that AE37 is a multipepi-
tope vaccine, capable of inducing both specific CD4+
and CD8+ T cells in vaccinated cancer patients [9]. The
AE37 vaccine encompasses the immunogenic epitope of
HER-2 p776-790 (the 15-mer AE36) which is subjected
to the Ii-key modification for enhancing recognition by
CD4+ T cells and also shows highly promiscuous binding
to a series of MHC class II alleles with various affinities,
as tested in binding and functional assays [44–46]. HLA
class II-matched peptides such as AE36, may be particu-
larly suited for activating CD4+ T cells in vaccination
protocols thereby enabling their extensive interactions
with other immune cells [6, 47]. We hypothesize that
AE37-induced T-helper cells may engage dendritic cells
at tumor sites, thereby cross-presenting antigens from
apoptotic tumor cells and inducing epitope spreading.
Herein, we have addressed this issue by testing on our
long-term survivors from the phase I trial for vaccine-
induced epitope spreading. To this end, we have used
MHC class I dextramers to identify both at baseline (i.e.
preexisting) and during vaccinations, T cell responses
(measured as % of dextramer-specific CD8+ T cells)
against other HER-2/neu epitopes or against epitopes
from other tumor antigens, representing intramolecular
and intermolecular spreading, respectively. Because epi-
tope spreading reflects an endogenous immunologic
response closely related to the broader spectrum of
tumor-specific preexisting immunity, we also analyzed
our vaccinated patients for preexisting immunity to the
vaccine by AE36-specific IFNγ-based ELISPOT assay and
by LR1. We also planned to evaluate whether preexisting
immunity to AE36 in combination with epitope spreading
was predictive of treatment benefit. With respect to the
latter, we analyzed frequencies of CD8+ T cells recognizing
CTL specific epitopes restricted by HLA-A2 or HLA-A24,
which are the most commonly expressed alleles among
our study patients. It has to be mentioned that statistical
significance could not be reached in many instances
mostly due to the very limited patient numbers compared
in each subgroup. However consistent trends can be inter-
preted as proof-of-principle data and require further con-
sideration. Our data demonstrated that patients with high
preexisting immunity to AE36, irrespectively of HLA-A2
or A24 expression, showed statistically significant longer
PFS, than patients with low AE36 preexisting immunity,
in accordance with our previous observation of improved
OS in these patients with high baseline IFN-γ response to
the peptide AE36 [10]. Similar results were also obtained
in a phase II clinical trial of breast cancer patients vacci-
nated with AE37 in the adjuvant setting [48]. To our
knowledge, this is the first observation which renders pre-
existing immunity to a long peptide vaccine as a predictive
biomarker, for the selection of patients most likely to
benefit clinically from vaccination.
Local reactions at different vaccinations cycles have
been recently correlated with improved clinical outcome
[30, 31]. Here, we propose for the first time LR1, i.e. the
local reaction (induration) 48 h after the first vaccine, in-
dicative of preexisting antitumor immunity, as a predict-
ive surrogate biomarker for immunological and clinical
responses in patients undergoing injections with AE37
and immunoadjuvant.
Based on our data, we detected preexisting immunity
for several HLA-A2 and HLA-A24 restricted tumor epi-
topes in patients expressing the respective alleles, which
(See figure on previous page.)
Fig. 5 Preexisting immunity to HLA-A2 and HLA-A24-restricted CTL epitopes affects progression free survival. HLA-A2+ patients having high
preexisting immunity to E75 showed a trend for shorter mPFS compared to them with low one (a). Patients with high Rmax/R0 had a trend
for decreased mPFS, compared to patients with low Rmax/R0 (b). No statistically significant differences were observed among patients having
high or low preexisting immunity to PSA146 and high or low Rmax/R0 (c, d). HLA-A24
+ patients having high preexisting immunity to PSA153
showed statistically significant longer mPFS compared to patients with low (e). No statistically significant differences were observed among
patients having high or low Rmax/R0 (f)
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was actually enhanced post AE37 vaccination. Of the
epitopes analyzed, the HLA-A2 restricted E75 and
PSA146–151 peptides as well as the HLA-A24 restricted
PSA153–161 peptide were the most immunogenic ones
based on their relatively high frequencies of CD8+ T
cells (>0.15 %) at baseline, which were even further
augmented during vaccinations. To unravel possible
predictive significance of preexisting immunity for clin-
ical outcome in our vaccinated patients, we correlated
frequencies of CD8+ T cells, at baseline and during vac-
cinations, specific for the E75, PSA146–151 or PSA153–161
peptides, with mPFS of patients carrying the appropriate
HLA restricting alleles. Our analyses showed that high
levels of preexisting immunity to PSA153–161 correlated
with significantly higher mPFS in HLA-A24+ patients,
whereas no such correlation was observed in HLA-A2
carriers with preexisting immunity to E75 or PSA146–154
peptides. In contrast to our expectations, HLA-A2+ pa-
tients with high preexisting or vaccine-induced immunity
to E75, showed a trend for shorter PFS than patients with
low levels of such immunity. This observation could be
explained by the assumption that although the immune
system of these patients had a preexisting memory for E75
and responded by epitope spreading post vaccination, in-
creasing epitope specific CTLs, they failed to interpret this
to an effective clinical response, due to possible changes
of the tumor immune profile. In line with this, results
from a clinical vaccination study in melanoma patients,
showed that no significant correlation was observed be-
tween clinical response and increases in the post vaccin-
ation peptide specific CD8+ tetramer+ T cells [49]. Despite
the fact that HLA-A2 may be an adverse prognostic factor
in prostate cancer [50], it has been previously described
that HLA-A2 along with HLA-C3 can predict prevention
of relapse in melanoma patients vaccinated with Melacine
[51]. Moreover, encouraging results have been reported in
a previous study, where HLA-A2 breast cancer patients
received trastuzumab therapy concomitantly with a
HER2/neu T-helper peptide-based vaccine, encompassing
HLA-A2 immunogenic motifs, including E75 [25].
It is well known that altered expression of HLA class I,
ranging from total loss to reduced expression of single loci
and alleles, has been found in high frequency in several
cancer types [52], including also prostate cancer [53], and
is a mechanism which accounts for the selective out-
growth of tumor-escape variants during immunoediting
[54–58]. Moreover, patients with prostate cancer and
HLA class I abnormalities in their lesions, have poorer
clinical outcome, than those with no detectable HLA class
I antigen abnormalities in their tumors [59].
HLA-A*02 genotype has been reported to be a strong
prognostic factor linked to the aggressiveness of ovarian
cancer of serous histology, prostate cancer and malignant
melanoma [60] with a selective loss found in these and
other types of cancer [47–49]. The underlying mechanism
for HLA-A2 loss has not been clarified yet. However, dif-
ferent hypotheses have been reported, such as up regula-
tion of miR-181a, in different types of cancer [61–64],
which has been previously associated with selective down-
regulation of HLA-A2 [65]. Another hypothetical ex-
planation of the poor prognosis that characterizes
HLA-A2+ patients, could be rather genetic than im-
munological [66].
Another possibility could be the well known conse-
quences of HER-2 expression on MHC class I restricted
antigen presentation machinery, which connect HER-2
overexpression with downregulation of surface MHC class
I expression [67–70]. These defects in components of the
antigen processing and presentation machinery, induced
by HER-2, obstruct the in vivo generation of class I re-
stricted HER-2 derived epitopes, haltering tumor recog-
nition by CTL [71]. To this end, Norell et al. showed that
metastatic ovarian tumor cells altered HLA class I expres-
sion through haplotype loss which was associated with in-
efficient HLA-A2-restricted immunity to HER-2 [72].
A third option could be that tumors with high expres-
sion of HER-2, as it is the case with progressed castrate re-
sistant prostate cancer [3–5], are often characterized by
alleviated capacity of being recognized by tumor antigen-
specific CTL. It has been previously reported that espe-
cially for E75 immunization protocols, E75 specific
vaccine-induced CTLs failed to recognize HER-2+ tumors
[73] and HLA-A2+-HER-2 overexpressing carcinomas,
even after IFNγ treatment [74]. This could explain our ob-
servation that patients with high preexisting immunity
against E75 and patients with induced E75-immunity
upon vaccination with AE37 demonstrated shorter PFS.
Our data are also supporting the notion that preexisting
AE36 immunity might be beneficial through induction of
antigen specific CD4+ T cells, with cytotoxic function,
that could successfully recognize tumor cells with
down-regulated HLA class I alleles. Vaccine- induced
CD4+ T cells with cytotoxic antitumor activities have
been previously described [12, 75, 76]. Another import-
ant aspect of preexisting AE36 immunity is the local
production of cytokines, such as IFNγ, by activated
CD4+/AE36+ cells, which could not only restore tumor
cells’ HLA class I loss, but also activate components of
innate immune system against tumor cells (e.g. NK cells,
eosinophils, macrophages and neutrophils).
Conclusions
Our data although hypothesis generating, still they raise
a very important issue by introducing an ambiguity
whether preexisting immunity or epitope spreading
specific for HLA-class I-restricted peptides can actually
predict a favorable clinical outcome. They further
strengthen the notion that peptide vaccines should
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contain HLA class II epitopes aiming at the activation of
Th cells in order to counteract selective outgrowth of
HLA class I negative tumor variants, under the pressure
of immune selection mediated by tumor specific cyto-
toxic T cells. Thus, preexisting immunity to long vaccine
peptides encompassing HLA class II, but also HLA class
I epitopes, may offer an advantage in the clinical out-
come of vaccinated patients, further contributing to the
improvement of future immunotherapeutic protocols.
Additional file
Additional file 1: Figure S1. Frequencies of CD8+ cells recognizing
HER85 (A), HER435 (B), PSMA (C), SURV96 (D), TERT (E) in HLA-A2
+ patients
and SURV20 (F) in HLA-A24
+ patients, at time points R0 and Rmax. Statistical
significant increase was observed for HER85 and TERT, while a strong trend
was observed for SURV96. (PPTX 249 kb)
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